Systemic Dickkopf-related Protein 1 (DKK1)During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors
| Status: | Completed |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | April 2011 |
| End Date: | August 2015 |
Systemic DKK1 During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors
The investigators are hypothesizing that decreasing estrogen levels will cause serum DKK1 to
peak, then decrease gradually as estrogens reach a new lower, but steady level. The
investigators also believe that the peak in DKK1 will initiated a wave of stem cell
diversion from the osteoblastogenic pathway to the adipogenic pathway.
The investigators will conduct a longitudinal cohort study of post menopausal women with
hormone-responsive breast cancer that will be treated AIs. The study will observe
anthromorphic and serum marker changes during the first year of their treatment.
peak, then decrease gradually as estrogens reach a new lower, but steady level. The
investigators also believe that the peak in DKK1 will initiated a wave of stem cell
diversion from the osteoblastogenic pathway to the adipogenic pathway.
The investigators will conduct a longitudinal cohort study of post menopausal women with
hormone-responsive breast cancer that will be treated AIs. The study will observe
anthromorphic and serum marker changes during the first year of their treatment.
Inclusion Criteria:
- Post Menopausal Breast cancer patients with planned treatment of aromatase
inhibitors.
- 18 years or older
Exclusion Criteria:
- BMI >30 or <18
- Osteoporosis as defined by protocol.
- Subjects currently on bisphosphonate therapy.
- History of primary or secondary hyperparathyroidism
- History of Hypo-or Hyperthyroidism
- History of Vitamin D levels below LLN
- History of creatinine clearance below the EGFR
- History ofLiver function tests above 1.5 times ULN including LDH, SGOT, SGPT,
Alkaline phosphatase, and Bilirubin
- History of documented cirrhosis of the liver
- History of chronic heparin use
- History of chronic glucocorticoid therapy
We found this trial at
1
site
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
